Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 31, 2023
- Pharmaceuticals
- R&D
Roche Announces Outcomes for EMBARK Study of Elevidys in Duchenne Muscular Dystrophy
TOKYO, October 31, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on October 30 (local time) regarding outcomes for EMBARK study in Duchenne muscular dystrophy (DMD) of microdystrophin gene therapy, ElevidysTM (Generic name: delandistrogene moxeparvovec, Development code: SRP-9001).
Please refer to the link below for details of the press release:
Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
https://www.roche.com/media/releases/med-cor-2023-10-30
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
